{"id":"NCT03312634","sponsor":"Clementia Pharmaceuticals Inc.","briefTitle":"An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.","officialTitle":"A Phase 3, Efficacy and Safety Study of Oral Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-11-30","primaryCompletion":"2020-01-24","completion":"2022-09-07","firstPosted":"2017-10-18","resultsPosted":"2023-03-14","lastUpdate":"2023-11-29"},"enrollment":107,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Fibrodysplasia Ossificans Progressiva"],"interventions":[{"type":"DRUG","name":"Palovarotene","otherNames":[]}],"arms":[{"label":"Palovarotene Chronic/Flare-Up Regimen","type":"EXPERIMENTAL"}],"summary":"Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by heterotopic ossification (HO) often associated with painful, recurrent episodes of soft tissue swelling (flare-ups) that lead to ankyloses of major joints with cumulative and irreversible loss of movement and disability.","primaryOutcome":{"measure":"Annualized New Heterotopic Ossification (HO)","timeFrame":"Baseline (within one month of screening/Day 1) and up to 24 months","effectByArm":[{"arm":"Palovarotene","deltaMin":9427.1,"sd":3084},{"arm":"Untreated (PVO-1A-001)","deltaMin":23720.2,"sd":4850}],"pValues":[]},"eligibility":{"minAge":"4 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":9},"locations":{"siteCount":16,"countries":["United States","Argentina","Australia","Brazil","Canada","France","Italy","Japan","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["21460849","37156007","36583535"],"seeAlso":["http://ifopa.org"]},"adverseEventsSummary":{"seriousAny":{"events":34,"n":107},"commonTop":["Dry skin","Lip Dry","Arthralgia","Drug eruption","Alopecia"]}}